2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

Portefølje Naturvitenskap og teknologi ikon

The research system

Portefølje Humaniora og samfunnsvitenskap ikon

Ground-breaking research

Portefølje Samisk ikon

Sámi society and culture

Portefølje Demokrati, styring og fornyelse ikon

Democracy and global development

Portefølje Velferd, kultur og samfunn ikon

Welfare, culture and society

Portefølje Helse ikon

Health

Portefølje Klima- og polarforskning ikon

Climate and environment

Portefølje Landbasert mat, miljø og bioressurser ikon

Land-based food, the environment and bioresources

Portefølje Energi, transport og lavutslipp ikon

Energy and transport

Portefølje Muliggjørende teknologier ikon

Enabling technologies

Portefølje Industri og tjenestenæringer ikon

Innovation

LTP Climate, environment and environmentally friendly energy

Climate and loss of natural diversity

Internationalization

Societal security and civil preparedness

Renewal in the public sector

Velferdstjenester

Frontpage Image

Marine icon

Petroleum og mineraler

LTP Hav ikon

Oceans and coastal areas

LTP2 Muliggjørende og industrielle teknologier ikon

Enabling and industrial technologies

Trust and community

Professional environment

High quality and accessibility

LTP Climate

Strengthened competitiveness and innovation capacity

LPT Health

 An innovative business community

LTP3 Helse

Portefolje Petroleum Ikon

Portefølje Hav ikon

Portefølje Utdanning og kompetanse ikon

Portefølje Global utvikling og internasjonale relasjoner ikon

Portefølje Livsvitenskap ikon

LTP2 Styrket konkurransekraft og innovasjonsevne ikon

LTP2 Utvikle fagmiljøer av fremragende kvalitet

LTP2 Samfunnssikkerhet og samhørighet ikon

LTP2 Fornyelse i offentlig sektor ikon

LTP2 Klima, miljø og miljøvennlig energi ikon

Forsidebilde optimalisert

project-bank-technical

Et innovativt næringsliv ikon

Muliggjørende teknologier bakgrunn

Marin bakgrunnsbilde

Marin ikon

Forsidebilde

Statistics

Prosjektbanken presenterer statistikk og informasjon om prosjekter med finansiering fra Forskningsrådet fra 2004. Statistikken er fordelt på blant annet tema, år, geografi og organisasjon. Prosjektbanken gir også detaljert informasjon om de enkelte prosjektene.

...or see the summary and other information about the projects you have selected

Portfolios

En god beskrivelse av denne siden for søkemotoroptimalisering

Forside

How the grants are distributed between organisations, counties, subject areas etc....

Here are some examples of searches you can perform in the Project Databank

All long term plan objectives

About Text Queries

No thematic area or topic related to the project

has received funding in the programme period

No popular science description is available

have received funding in the programme period

The project with project number {{project number}} was not found

Technical description

Woops, something went wrong. Please refresh the page. If the error persists, please contact us.

We could not find what you were looking for

See statistics related to this LTP objective

See projects related to this LTP objective

related to this LTP objective have received grants

has been granted to projects related to this LTP objective

has been granted to projects related to this portfolio

related to this portfolio have received grants

About Prosjektbanken

Programmer

Frittstående prosjekter

Nettverkstiltak

Infrastruktur og institusjonelle tiltak

Forvaltning

Diverse FoU-relaterte aktiviteter

Felleskostnader

Ukjent

Reality-Connected Machine Simulation of Heavy Machinery

The RealSim project proposal aims to connect machine simulation to reality in the framework of heavy machinery, which is an interdisciplinary application. The results of this project are expected to optimize machine performance, accurately and reliably predict machine failure, and reduce overall development and operation costs, thus, serving the Europe’s priority of green transformation and the United Nation’s sustainable development goal 9. The RealSim project will close the gaps of: (1) Onboard estimations of force and pressure components of heavy machinery; (2) Estimating deformability, cylinder friction, leakage, and valve dynamics of heavy machinery using independent nonlinear Kalman filters; (3) Employing dependent nonlinear Kalman filters in state estimators of heavy machinery; (4) Tuning algorithms for the covariance matrix of plant noise in the state estimation of heavy machinery. 

I will consolidate and leverage my research career and position as a leading researcher in the field through integration in Assoc. Prof. Mohammad Poursina’s group at the Department of Engineering Sciences of the University of Agder (UiA), Norway. Here, I will acquire hands-on experience of working with actual mechatronic systems and develop efficient control algorithms. I will improve my knowledge of fluid power designing, control theory, instrumentation, and develop efficient coding skills. I will also develop entrepreneurial skills. The skills, knowledge, and international network that I will develop during this fellowship will put me in an excellent position to achieve my long-term goal of becoming a professor with my own independent research group at an esteemed university in EU. This fellowship will help me to prepare a strong ERC Starting Grant application in the future. It will also cater my additional goal of setting-up a research-related start-up in the future.

Algebraic Theory of Information Quantities

Information theory is a discipline at the intersection of statistics, engineering and computer science. As the study of information quantities, such as compression or communication capacities, information content or measures of statistical dependency, it is one of the theoretical underpinnings of data science.

Computational problems in information theory are highly non-linear. The goal of this project is to transfer state-of-the-art methods of computational non-linear algebra to information theory, to study the inherent algebraic complexity of information-theoretical problems and to provide tools for solving them in practice. The algebraic point of view has proven to be fruitful in seemingly unrelated areas, as witnessed by a surge of recent work in algebraic statistics, in particular on likelihood geometry. However, maximizing the likelihood function is the same as minimizing relative entropy — a specific information quantity. Hence, this project also aims at generalizing the techniques developed in likelihood geometry.

One focus is on the practical computation of information quantities using numerical and differential algebraic geometry. Such quantities are defined via non-linear optimization problems and we aim to pinpoint the algebraic complexity of these problems in instances of general interest, such as common information measures. The final objective is finding fundamental laws and limits of data science imposed by non-linear inequalities constraining the entropic region. These inequalities provide, by duality, universal bounds for many of the optimization problems studied in information theory.

WHeelchair Activity Monitoring project (WHAM)

Wheelchair users (WCU) are three to five times more inactive than the general population, leading to a high risk of developing preventable secondary conditions. Although physical activity (PA) guidelines have been specifically developed for WCU, we lack systematic approaches to implement them in practice, as well as valid algorithms to monitor PA change in WCU through sensor-based solutions. Accordingly, the overall scientific aim of the WHeelchair Activity Monitoring project (WHAM) is to advance PA research and practice in WCU by developing valid digital markers for monitoring of and providing feedback on PA, paving the way for implementation and intervention. I will accomplish this through combining the complementary research fields of 1) behavioural intervention studies focusing on increasing PA in WCU (core competence University of British Columbia, UBC; outgoing phase) and 2) sensor-based PA monitoring (core competence Norwegian University of Science and Technology, NTNU; returning phase – consolidated by non-academic placement at Maastricht Instruments, which develop research prototypes including PA monitors). WHAM’s scientific aim is achieved through three objectives: 1) Measure the effect of a pragmatic exercise intervention trial on self-reported physical activity levels and cardio-respiratory fitness, 2) Develop valid algorithms for tracking PA markers in WCU, and 3) Co-create a framework that outlines how PA can be conjointly monitored and provided feedback on in WCU. This fellowship will enable me to become established as an internationally recognized researcher in the field of “physical activity and disability”, while bringing together ongoing national disjointed research activities in this field. Altogether, my overall ambition is to contribute to reducing inequalities in daily-life participation among WCU compared to the rest of the population.

EOSC Beyond: advancing innovation and collaboration for research

EOSC Beyond overall objective is to advance Open Science and innovation in research in the context of the European Open Science Cloud (EOSC) by providing new EOSC Core capabilities allowing scientific applications to find, compose and access multiple Open Science resources and offer them as integrated capabilities to researchers. To do so, EOSC Beyond supports a new concept of EOSC: a federated and integrated network of Nodes operated at different levels, national, regional, international and thematic, to serve the specific scientific missions of their stakeholders. Further specific objectives of the project are to accelerate ‘time to product’ of new scientific applications with software adapters, enable Open Science with machine composability and dynamic deployment of shared resources, support innovation in EOSC with a testing and integration environment, and align the EOSC Core architecture and specifications to integrate with European dataspaces. The project extends the state of the art of the EOSC Core and adopts a co-design methodology, including requirements elicitation, software development and validation in collaboration with different use cases from EOSC national and regional initiatives (e-Infra CZ, Czechia, NFDI, Germany, and NI4OS, South East Europe region), thematic research infrastructures from Social Sciences and Humanities (CESSDA), Life Sciences (CNB-CSIC and Instruct-ERIC), Environmental Science (ENES and LifeWatch), and Health and Food (METROFood-RI). EOSC Beyond builds on the capacities of prospective EOSC Nodes and partners with multi-annual experience in developing solutions for large-scale federated digital infrastructures and aligns with the technical architecture and requirements of data spaces from different business sectors. Ultimately, EOSC Beyond supports Open Science in modern, data-intensive, and multidisciplinary research, facilitating resource discovery, access, and reuse across scientific communities, organisations, and countries.


Harmonization of Advanced Materials Ecosystems serving strategic Innovation Markets to pave the way to a Digital Materials & Product Passport

The overarching objective of DigiPass is to enhance the digital maturity of the European communities that develop materials and intermediate products. The project will develop recommendations and clear routes toward digitalized circular business models. The overarching key result of DigiPass is to create a sustainable platform which includes support for Digital Materials & Product Passport and for collaborative innovation-by-design processes in a circular economy served by advanced materials. A business model for operating such a platform completes the overarching objective.
DigiPass is harmonizing and synergizing collected materials data sources and digital infrastructures. This will enable interoperability of data exchange, and standardization of advanced materials knowledge representation at all maturity levels. Accelerating the design, development, and production of advanced, safe, and sustainable chemicals and materials, as they are necessary for innovative products, calls for a collaborative approach involving different stakeholders to support durability, repair and overhaul, reuse, and recyclability of products. DigiPass project impacts all materials development communities over the whole circular value chain. 


Enhanced X(cross)-disciplinary Community-driven Imaging Technologies for Earth and Environmental material research

The EXCITE² Network is revolutionizing Earth and environmental material science research by consolidating a critical mass of 18 research facilities in 12 European and associated partner countries into a unified infrastructure and providing transnational access to advanced imaging technologies. This enables scientists to decipher complex processes within Earth materials at scales from nanometres to hundreds of centimetres, gaining unparalleled insight into the chemical and physical processes that govern, among others, environmental toxicity and its impact on human health, critical metal extraction for renewable energies, and the utilisation of Earth materials as long-term storage for climate-altering gases. The consortium fosters knowledge-sharing and talent attraction, bolstering the problem-solving capacity of the European Research Area. Moreover, EXCITE² is driving interdisciplinary collaboration and cross-fertilisation across academic institutions, scientific disciplines, and industry, propelling Europe towards a sustainable future. The initiative offers dedicated training programmes to a new generation of researchers within the European open science landscape, paired with access to world-class imaging facilities and expertise for problem-solving research and innovation. EXCITE² is introducing innovative service developments, such as artificial intelligence and leading-edge imaging experiments, to increase the user's problem-solving capacity. In addition, the consortium is implementing customised project valorisation strategies to maximize the impact of research outcomes in academia, society, and the economy. Citizen science projects allow the public to participate directly within the EXCITE² Network, contributing to solving EU challenges. As such, EXCITE² is paving the way towards a sustainable future, driving scientific excellence, and creating positive societal impact.

Engineering carbon quantum dots for zinc ion hybrid capacitors

Zinc ion hybrid capacitors (ZIHCs) integrate two energy storage mechanisms of battery-type electrode and capacitive electrode, bearing the advantages in energy density, power density, and safety. Until now, the cycle retention rate of ZIHC's capacity reported is still not more than 80%, restricting its development and commercial application severely. Focusing on the issue, the project aims at overcoming the limitation of traditional electrode materials and re-defining the designing concept to construct Carbon Quantum Dots (C-QDs) for ZIHCs. Advanced methods will be used to harvest carbon quantum dots from coal tar pitch (a sort of industrial solid castoff). The bulk sp2-carbon network, innumerable edge sites, profuse surface functional groups, and regular size ensures that as-synthesis C-QDs have high electrical conductivity, sufficient ion transport channels and rich adsorption sites. Moreover, the new concept of dynamic evolution is introduced for insight into the structure and interface failure of ZIHC's electrode. The interface-reconstruction mechanism and the attenuation model of capacity will be established for the first time. Further, the methods to strengthen structures of C-QD electrode will be developed based on a trade-off strategy. The ultimate goal is to improve the energy storage efficiency of ZIHCs by 20% and to increase their cycle performance more than 95% unprecedentedly. This research will develop long-running high performance ZIHCs, for contributing European energy storage industry. The ER will achieve abundant research experience and scientific skills from the project and the capability to launch her own research group in future.

Aqua Research Infrastructure Services for the health and protection of our unique, oceans, seas and freshwater ecosystems

AQUARIUS will provide a highly comprehensive suite of integrated research infrastructures appropriate to addressing significant challenges for the long-term sustainability of our unique oceans, seas and freshwater ecosystems. For the first time, diverse research infrastructures will be combined to facilitate the work of researchers and key stakeholders focused on challenges and opportunities for both marine and freshwater systems. An impressive range of 57 research infrastructure services will be made available to include research vessels, mobile marine observation platforms, aircraft,  drones, satellite, sensors, fixed freshwater and marine observatories and test sites, experimental facilities, and sophisticated data infrastructures. AQUARIUS will support the development phase of the EU Mission to Restore our Ocean and waters by 2030, the Sustainable Blue Economy Partnership, the European Green Deal, and international climate initiatives. It will also be an essential component in achieving the European Digital Twin of the Ocean and the UN Decade for Ocean Sciences. The needs of researchers will be met through a robust and transparent system of transnational access funding Calls, facilitated by centralised user-friendly access portal. The Call programme will be informed through stakeholder engagement and brokerage events. Projects to be selected for Access must convincingly integrate multiple infrastructures and contribute to the core policy objectives of Mission Ocean, that is, to protect and restore marine and freshwater ecosystems and biodiversity; to prevent and eliminate pollution of our oceans, seas and waters; and to ensure a sustainable, carbon-neutral and circular blue economy. A thematic and geographic focus will be the hallmark of the proposed transnational Calls, aligning with the Lighthouse Regions, that is, the Baltic and the North Sea Basins, Black Sea, Atlantic/Arctic, and Mediterranean Sea along with their associated rivers.

EOSC-ENTRUST: A European Network of TRUSTed research environments

The mission of EOSC-ENTRUST is to create a European network of trusted research environments for sensitive data and to drive European interoperability by joint development of a common blueprint for federated data access and analysis. 
Countries and institutions have made significant investments in secure and trusted data environments to meet the need for research and policy-driven analysis of sensitive datasets such as people's health and socio-economic status, the habitats of vulnerable species and geo-spatial locations of protected sites. There are now a large number of such secure environments in operation - linked to national centres, individual organisations or specific research communities. This fragmented landscape poses challenges for both users and providers: researchers are faced with a large number of different systems and access procedures; providers need to manage federated access across multiple, potentially incompatible, technology and governance frameworks.
EOSC-ENTRUST brings together providers of operational Trusted Research Environments from 15 European countries with a shared goal to implement, validate and promote their capabilities through a common European framework using shared standards and common legal, operational and technical language. This blueprint for interoperability is anchored in the EOSC Interoperability Framework spanning the four dimensions of Legal, Organisational, Technical and Semantic interoperability. EOSC-ENTRUST has identified four driver projects covering Genomics, Clinical trials, Social science, and public-private partnerships to benchmark capabilities, inform blueprint design and demonstrate secure  data analysis using federated workflows.
Targeted outreach activities will expand this open network with further providers and develop policy papers and guidelines for the full range of stakeholders to create a long-term operational TRE framework within the European Open Science Cloud.


IMProving User experience, Long-term sustainability and Services of EU-OPENSCREEN

EU-OPENSCREEN (EU-OS), the distributed European Research Infrastructure for Chemical Biology and early drug discovery, provides world-class services in high-throughput compound screening and medicinal chemistry to users from academia and industry. As one of the largest open-access initiative globally, EU-OPENSCREEN plays an increasingly important role in facilitating early stage drug discovery in Europe. It recently integrated fragment-based drug discovery and chemoproteomics as two new services, but the increasing complexity of modern drug discovery projects requires an even more comprehensive portfolio and integration of emerging technologies. To ensure that EU-OS continues to offer a comprehensive suite of relevant services and support a growing user community to conduct forefront research, IMPULSE will develop, validate and integrate new services in AI/ML, new chemical modalities, and innovative disease-relevant cell models combined with CRISPR-Cas9/RNAi-based genetic screening. IMPULSE will work towards the implementation of common operational and data standards to increase data reproducibility and FAIRness. Bespoke outreach and training activities will raise awareness among key user groups of its new services and advance operational excellence and reproducibility in pre-clinical drug discovery. New models for pre-competitive drug discovery with industry or charities, and growing ERIC member community will reinforce the sustainability and accessibility of EU-OPENSCREEN.

Midlene fra BALANSE-Kjønnsbalanse i toppstillinger og forskningsledelse fordelt på år

Midlene fra BALANSE-Kjønnsbalanse i toppstillinger og forskningsledelse fordelt på fylker

Midlene fra BALANSE-Kjønnsbalanse i toppstillinger og forskningsledelse fordelt på fagområde

Forskingssjef

«Equality in sigth» er eit prosjekt for kjønnsbalanse og mangfald ved Høgskulen i Volda, og det gir tilgang til deltaking i den nasjonale BalanseHuben (2024-2026). Formålet med «Equality in sight» er at fleire kvinnelege tilsette skal oppnå opprykk til første- og toppkompetanse gjennom støtte og målretta jobbing med vitskapleg publisering og søknader om eksterne forskingsprosjektmidlar. HVO har utfordringar med kjønnsbalanse og treng å auke medvitet om mangfald. Deltakinga i BalanseHuben vil vere med på å sette fokus på korleis Høgskulen i Volda kan arbeide for å nå måla om kjønnsbalanse. HVO vil motivere og støtte kvinner til å satse på ein forskarkarriere, mellom anna gjennom kvinnenettverket, og auke mangfaldet.   

Prosjektet er forankra i leiinga med forskingssjef som prosjektleiar. Vi søker også om ei stilling i 30% som skal bidra til å organisere og gjennomføre tiltaka og kvinnenettverket.  

HVO har gode opprykksprogram i form av ph.d. i ei 50/50 ordning og professor-/dosentstipend, og dei siste åra har kvinner vore tildelt omlag halvparten av midlane frå desse ordningane. Dette gir forskingstid og høve til å bygge kompetanse hos den enkelte, men det endrar ikkje strukturane og kulturen som kan hindre kvinner i å søkje og oppnå opprykk. Forsking og statistikk viser at det er høgare sannsynlegheit for at mannlege enn kvinnelege førsteamanuensar vert professorar. Vi vurderer at vi må jobbe meir strategisk og arbeide målretta med strukturelle, kulturelle og historiske årsaker til manglande kjønnsbalanse og lite mangfald. Det handlar ikkje om å kvotere, men om å motivere kvinner og innvandrarar til å satse på ein akademisk karriere og å ha dei rette strukturane på plass for å støtte dei i dette. Dei mest sentrale utfordringane vi forventar å møte i prosjektet er nettopp å treffe med dei gode løysingane som gjer at kvinner får moglegheit til å prioritere eit akademisk karriereløp og å rekruttere fleire vitskaplege tilsette som er etterkommarar av innvandrarar.

Equality in sight: Balanse og mangfald ved Høgskulen i Volda

Pasienter med kreftsykdom har særlig høy risiko for å utvikle underernæring, både på grunn av sykdommen i seg selv og på grunn av effektene kreftbehandling kan ha på appetitt, smaksopplevelse, kvalme og utmattelse. Noen kreftpasienter utvikler også kreft kakeksi, et multifaktorielt syndrom som kjennetegnes av ufrivillig vekttap og anoreksi. Tidligere studier har vist at underernæring og vekttap blant kreftpasienter kan føre til økt lengde på sykehusopphold, redusert muskelfunksjon, forsinket sårtilheling, redusert toleranse for kreftbehandling, lavere livskvalitet og økt mortalitet. 

Tidligere studier har vist at sykehusinnlagte pasienter med underernæring har tre ganger lengre sykehusopphold sammenliknet med pasienter som ikke har underernæring. British Association for Parenteral and Enteral Nutrition (BAPEN) har estimert at behandling av pasienter med underernæring koster over 7 milliarder pund per år i Storbritannia. 

Tilgang til medisinske ernæringsprodukter som er tilpasset pasientgruppen er essensielt for å redusere de alvorlige konsekvensene underernæring kan føre til for den individuelle pasient og for å redusere de økonomiske kostnadene underernæring kan føre til for samfunnet. Dette er bakgrunnen for innovasjonsprosjektet «Nytt fullverdig næringsmiddel til spesielle medisinske formål», som har som mål om å utvikle nye medisinske ernæringsprodukter som er tilpasset pasientgruppen med kreftsykdom. 

Et utvalgt av kompetente forskere og fagpersoner fra Smartfish, SINTEF, universitetet i Bergen og Universitetet i Lund skal samarbeide for å lykkes med dette prosjektet. I løpet av det første året vil arbeidsoppgaver fokuseres på produktformulering. Dette inkluderer valg av råmateriale, beslutning om hvordan råmateriale skal blandes i produktet og forskning på stabiliteten til produktet over tid. I tillegg vil mye tid i løpet av det første året bli brukt til forberedelser av de kliniske studiene som har planlagt oppstart i 2023 og 2024.

Smartfish AS skal i dette prosjektet samarbeide med SINTEF AS, Universitetet i Bergen og Universitetet i Lund med å skape og forske på et nytt ernæringsmessig fullverdig næringsmiddel til spesielle medisinske formål (Food for Special Medical Purposes – FSMP) til pasienter med kreftsykdom.

Siden 2018 har Smartfish produsert og solgt ca. 8 millioner av det nåværende juicebaserte FSMP-produktet for pasienter med underernæring og kakeksi. To randomiserte, dobbelt-blinde, kontrollerte kliniske studier har blitt gjennomført på nåværende produkt på pasienter med kakesi. Den kliniske studien som ble gjennomført på pasienter med non-small-cell lung cancer (NSCLC, lungekreft) viste blant annet at pasienter som inntok produktet hadde en positiv effekt på vitale tegn og lipidprofil, en trend til bedre toleranse for kjemoterapi og god toleranse for produktet. Etter ett år hadde 10 pasienter i placebogruppen avgått med døden, mot 4 pasienter i intervensjonsgruppen.

Med bakgrunn i resultater fra tidligere gjennomførte kliniske studier på nåværende medisinske ernæringsprodukt i tillegg til opparbeidet kunnskap om pasientbehov for målgruppen samt innhold i reguleringer som gjelder for FSMP-produkter, skal vi utvikle og forske på et nytt fullverdig FSMP-produkt til pasienter med kreftsykdom. Resultater fra dette prosjektet vil føre til ledende forskningsbasert ernæringsbehandling til pasienter med kreft kakeksi.

Nytt fullverdig næringsmiddel til spesielle medisinske formål

Cancer cachexia occurs in approximately 30–50% of all cancer patients, depending on type and stage (up to 86% of advanced cancer patients), creating approximately a 3-million annual incident patient population in the US, Europe and Japan.  Chronic obstructive pulmonary disease (COPD) Cachexia is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.

The market entry model will be developed further during the proposal preparation stage together with the partners. In particular, on-line distribution model will be developed to reflect the situation our distributors are facing during the COVID-19 outbreak.

Our estimates show that the product can generate revenues for Smartfish in order of €100 Mn in 5 years post-launch.

“Remune” portfolio expansion to nutritionally complete product, production scale-up and business development including on-line marketing

“Medical nutrition therapy” (MNT) is the use of specific nutrition services for the nutritional management of patients suffering from a disease related malnutrition, illness, injury, or condition. It involves the assessment of the nutritional status of the patient and the relevant nutritional intervention treatment, which includes nutrition therapy, counselling, and the use of specialized nutrition supplements.

The global medical nutrition industry is a €10-billion industry. As the various positive effects of medical nutrition solutions are becoming more evident, the industry is developing fast. Also, there is a strong trend towards tailor-made nutritional solutions. As a result, the market for medical nutrition shows an annual growth rate of 6.4% (Transparency Market Research “Global Medical Nutrition Market, 2018).

Smartfish targets cachexia patients. We have an evidence-based strategy currently focusing on the unmet medical needs of pre-cachexia and cachexia indications in oncology and COPD. Malnutrition in chronic diseases, such as COPD and cancer, strongly contributes to increased health care costs, partly because of the rapid increase in chronic lifestyle diseases and in age-related diseases worldwide. Many hospitalized patients are malnourished. Hence, governments promote and/or reimburse medical nutrition to reduce complications and hospital bed time.

Our estimates show that the developed product and production process can generate revenues for the Consortium partners in order of €90-120 Mn in 5 years post-launch.

Developing a cost-effective production of a novel omega-3 based advanced medical nutrition therapy product for international markets

Smartfish har flere drikker på markedet rettet mot både spesielle medisinske formål og mot idrettsutøvere for å forbedre restitusjon og immunforsvar. Drikkene er rike sammensetninger av fiskeolje, naturlige antioksidanter, myseproteiner, fiber og vitamin D. En viktig ingrediens og råvare i alle Smartfish produkter er DHA EPA fettsyrer fra marin olje, et bi-produkt av den norske fiskeindustrien. Studier har blitt gjennomført for bruk av drikkene til ulike medisinske formål slik som inflammasjon, KOLS, kreft, Alzheimers, diabetes, hjerte/karsykdommer og muskelrestitusjon. Resultatene viser at den patentbeskyttede Smartfish-formuleringen gir økt stabilitet og opptak av både fiskeolje og oljeløselige komponenter fra tarm. 
Prosjektets overordnede mål var å utvikle et nytt og effektivt oralt leveringssystem for behandling av kreft og infeksjonssykdommer. Ideen gikk ut på å kombinere Smartfish-drikkene med medisiner enten som adjuvant behandling eller i en nanoformulering. Tatt i kombinasjon med spesifikke legemidler vil man kunne oppnå en mer helhetlig effekt der man i større grad skaper balanse og støtter kroppens helse. 
Prosjektet ble gjennomført som et tett samarbeid mellom Smartfish og SINTEF.
Prosjektet har utviklet stabile formuleringer og det er gjennomført flere studier i cellekulturer som viser god effekt av de nye formuleringene. I tillegg har vi vist at Smarfish-drikker gitt som adjuvans til legemidler gir en forbedret effekt sammenlignet med legemiddel alene. Avanserte cellebaserte studier og bioanalytiske metoder ble utviklet for å bestemme opptak av legemidler og deres nedbrytningsprodukter over tarm og distribusjon av disse forbindelsene i mus. Det ble vist at Smartfish-formuleringen ga høyere opptak av aktive stoffer over tarm, og at Smartfish-formuleringene ga en  anti-inflammatorisk effekt i mus. Resultatene vil bli publisert i vitenskapelige publikasjoner.
Neste trinn vil være å utvikle Smartfish-drikkene/formuleringene videre og gjennomføring av kliniske studier.

This innovation project will develop drink-based therapeutic products that enable more effective treatment of cancer, infectious diseases and other inflammatory conditions. The improved treatment will have invaluable impact on well-being of patients and will have wider socioeconomic benefits through reduced costs of treatment.
Effective oral administration of poorly soluble or unstable drugs represent a holy grail for the pharmaceutical industry, and a proven technology delivering this could claim essentially unlimited market value through competitive advantages such as reduced need of hospitalization, ability to increase dosing frequency, improved patient adherence to long-term therapies, extended patent coverage and facilitation of global drug distribution including third world countries. 
Smartfish is a Norwegian SMB who manufacture and produce nutritional drinks containing marine oil, natural antioxidants, whey protein, fiber and vitamin D. They have demonstrated improved immune response and anticancer effect of curcuminoids and omega-3 fatty acids, compared to these agents taken in the dilute form. The patented Smartfish formulation has increased stability and uptake of both marine oil and oil soluble components from the gut compared to single administration of the compounds. Thus, we aim to prove that novel formulations based on Smartfish technology can be used for improved oral administration for a wide range of drugs, with particular focus on anticancer and antimicrobial agents.
A broad range of advanced methods will be employed to develop, characterize and produce novel drug-containing nanoformulations as well as Smartfish formulation and drug combinations. High-throughput screening will be used to select the most favorable formulations, drugs, and combinations thereof for in vivo studies. 
The project has great potential for value and IP creation, but also a high research need. Considering its broad scientific challenges, the realization of the innovation will require external expertise from SINTEF.

Smartfish NutriDrug: Efficient oral drug delivery system for the treatment of cancer and infectious diseases

Smartfish AS utvikler et produkt innenfor kategorien Mat for Spesielle Medisinske Formål, kalt Nutrifriend Cachexia (NF Cax, kommersielt navn er Remune). Produktet har som mål å redusere og motvirke skadene og den ofte dødelige utgangen av kakesi i  kreft (muskelsvinn syndrom hos pasienter under kjemoterapibehandling) og bedre livskvaliteten hos pasienter som lider av ulike former for kreft. Remune inneholder omega-3 i en juicekomposisjon med vitaminer og proteiner. Ingen næringsprodukter har hittil klart å vise bedret utfall for denne sykdommen.
Den kliniske studien i non small cell lung cancer (NSCLC, lungekreft) er  avsluttet og resultater ble presentert på kongressen for Sarcopenia Cachexia Wasting Disorder (SCWD) i Roma i desember.  Resultatene viser at pasienter behandlet med Remune tolererer cellegiftbehandlingen bedre enn pasienter behandlet med alternativ ernæring med samme kaloriinnhold (sammenligningsgruppen). Den randomiserte, dobbelt-blinde, kontrollerte kliniske studien viser også at Remune tolereres vel og har en god trygghetsprofil hos pasienter med (tidlig) kakeksi og ikke-småcellet lungekarsinom (ca 85% av lungekrefttilfellene). Remune har positiv effekt på vitale tegn og lipidprofil, og viser positive trender for cellegifttolerabilitet. Etter ett år hadde 10 pasienter i sammenligningsgruppen avgått med døden, mot 4 pasienter i Remune-gruppen.
Disse resultatene vil bane vei for kommersialisering av Remune i markedet og utløse videre klinisk forskning i kakektiske populasjoner.

The idea is to develop the next generation Food for Special Medical Purposes (FSMP) product(s) that;
- Reduce and/or counteract the damaging and often deadly outcome of cachexia (muscle wasting syndrome in cancer patients during chemotherapy treatment)
- Improve outcomes and quality of life in patients suffering from specific cancer types. 

The products that will be improved and documented will contain essential nutrients (marine omega-3 fatty acids, a polyphenol rich juice protecting the omega-3 from being oxidized, vitamin D3, protein and dietary fibre) known to exert a range of biological activities and influence cell function, immune functions and anabolic response etc. 

Through these effects, supplementation can directly influence cancer cells and the right combination of these nutrients can stimulate an anabolic response by counteracting factors involved in inducing and sustaining cancer cachexia.  No FSMP product to date has tried to or succeeded in demonstrating improved outcomes in cancer cachexia. 

The project consists of the following parts:
1) Preclinical development aiming to document the safety and efficacy of using nutrients in cancer treatment and which cancer that would benefit most from the treatment
2) Preclinical development aiming to understand the mechanisms behind the effects in cancer cachexia.
3) Clinical development aiming to document the safety and tolerability in patients as well as establishing the optimal efficacy parameter for further development
4) Clinical development documenting the efficacy in cancer cachexia 

The outlined research activities will lead to a new product for management of cancer cachexia in most likely non-small-cell-lung-cancer. The product will be unique among clinical nutrition products in the market. A full launch is foreseen in 2018 based on pivotal data and further regulatory approvals.

0 projects

BIA-Brukerstyrt innovasjonsarena

Nytt fullverdig næringsmiddel til spesielle medisinske formål

Awarded: NOK 7.8 mill.

Project Period: 2022-2024

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

“Remune” portfolio expansion to nutritionally complete product, production scale-up and business development including on-line marketing

Awarded: NOK 74,999

Project Period: 2020-2020

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

Developing a cost-effective production of a novel omega-3 based advanced medical nutrition therapy product for international markets

Awarded: NOK 99,999

Project Period: 2020-2020

Location: Oslo

NANO2021-Nanoteknologi og nye materiale

Smartfish NutriDrug: Efficient oral drug delivery system for the treatment of cancer and infectious diseases

Awarded: NOK 6.5 mill.

Project Period: 2016-2019

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

Smartfish juice for the treatment of cancer cachexia in combination with chemotherapy

Awarded: NOK 11.7 mill.

Project Period: 2015-2017

Location: Oslo